Patents Assigned to Neurogen Corp.
  • Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
    Patent number: 7081458
    Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: July 25, 2006
    Assignee: Neurogen Corp.
    Inventors: Alan J. Hutchison, John M. Peterson, Dario Doller, Wallace C. Pringle, Helen Yin
  • Certain alkylene diamine-substituted heterocycles
    Patent number: 7074929
    Abstract: This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: July 11, 2006
    Assignees: Neurogen Corp., Pfizer, Inc.
    Inventors: Raymond F. Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • 4-imidazol-1-ylmethyl-pyrimidine derivatives
    Patent number: 6951864
    Abstract: The invention provides 4-imidazol-1-ylmethyl pyrimidine of the formula that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: October 4, 2005
    Assignee: Neurogen Corp.
    Inventors: Linghong Xie, Bingsong Han, Yuelian Xu, George D. Maynard
  • Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
    Patent number: 6906075
    Abstract: Melanin concentrating hormone receptor ligands (especially substituted benzoimidazole analogues), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: June 14, 2005
    Assignee: Neurogen Corp.
    Inventors: Robert W. DeSimone, Cheryl Steenstra, Linda Gustavson, Rajagopal Bakthavatchalam, Alan Hutchison
  • Substituted tetrahydroisoquinolines as C5a receptor modulators
    Patent number: 6777422
    Abstract: Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: August 17, 2004
    Assignee: Neurogen Corp.
    Inventors: Kyungae Lee, Scott Mitchell, Robert Ohliger, Lu Yan Zhang, He Zhao, Kevin Currie